FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
Related Articles
Toripalimab Plus Chemo: A First-Line Option for ES-SCLC? – Oncology Nurse Advisor
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
A Quick Start Guide to Cancer Data Science for Clinical Oncology | CBIIT
Whether you are in the data science field, interested in developing computational solutions for clinical oncology, or a clinical researcher, we’ve curated a list of…
Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis
Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.
Research Aims to Expand RAS Inhibitor Options in Pancreatic Cancer
Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.
Incidence and Characterization of Secondary CNS Lymphoma in 1,972 Patients with DLBCL – A Danish Nationwide Cohort Study
Key Points. The cumulative incidence of SCNSL was 2.6% at two years with death and relapse without CNS involvement as competing risksThe most significant p
Advancing Predictive Biomarkers for Colon Cancer Treatment : Oncology Times
An abstract is unavailable.
COMPARABLE OUTCOMES AFTER BUSULFAN- OR TREOSULFAN-BASED CONDITIONING FOR ALLO-HSCT IN CHILDREN WITH ALL-RESULTS OF FORUM
Key Points. Chemo conditioning with busulfan- or treosulfan-based regimens yields comparable outcomes for allo-HSCT in children with ALL.Either regimen can
